Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) generates frequent news as it advances antibody-based therapies in immunology, with a particular emphasis on mast cell–driven diseases. Company updates often center on barzolvolimab, a humanized monoclonal antibody targeting the KIT receptor on mast cells, and CDX-622, a bispecific antibody that neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells via stem cell factor (SCF) starvation.
News coverage for Celldex commonly includes clinical trial milestones across multiple indications. For barzolvolimab, the company reports data from Phase 2 studies in chronic spontaneous urticaria (CSU) and chronic inducible urticarias such as cold urticaria (ColdU) and symptomatic dermographism (SD), describing statistically significant improvements in urticaria activity scores, provocation tests and quality-of-life measures, along with favorable safety profiles. Investors and clinicians can also follow announcements about the global Phase 3 EMBARQ-CSU program in CSU and the registrational Phase 3 EMBARQ-ColdU and SD program in ColdU and SD.
Additional Celldex news items highlight expansion of the barzolvolimab program into prurigo nodularis and atopic dermatitis, as well as strategic decisions such as discontinuing development in eosinophilic esophagitis (EoE) after a Phase 2 study showed mast cell depletion without clinical benefit. Updates on CDX-622 provide insight into early-stage safety, pharmacokinetics and pharmacodynamics, including sustained reductions in serum tryptase in healthy volunteers.
Corporate news may feature quarterly financial results, leadership appointments and participation in healthcare and investor conferences. For readers tracking CLDX, this news stream offers a view into Celldex’s progress in mast cell biology, the evolution of its clinical pipeline and key regulatory and financial disclosures. Bookmarking this page allows ongoing access to company-issued press releases and related market-relevant developments.
Celldex Therapeutics (Nasdaq: CLDX) has initiated enrollment for a Phase 1 open-label study of CDX-527, aimed at patients with advanced solid tumors. CDX-527 is a novel bispecific antibody designed to enhance anti-tumor T cell responses by combining PD-L1 blockade with CD27 costimulation. The trial will evaluate safety, maximum tolerated dose, and anti-tumor activity across various endpoints, enrolling approximately 90 patients. Previous data suggests CDX-527 could outperform existing treatments, bolstering its potential in the Celldex pipeline.
Celldex Therapeutics (Nasdaq: CLDX) is set to announce its second quarter 2020 financial results on August 6, 2020, after market close. A conference call will follow at 4:30 p.m. EDT, where executives will discuss the financial outcomes and provide updates on ongoing research and development initiatives for the remainder of 2020. The call will be accessible via the company’s website, and a replay will be available post-event. Celldex focuses on developing targeted therapeutics for severe diseases, utilizing immunotherapies and biologics to enhance treatment options for cancer and other illnesses.
Celldex Therapeutics (CLDX) has successfully closed an underwritten public offering of 15,384,614 shares at $9.75 each, generating approximately $150 million in gross proceeds. This includes the full exercise of the underwriters' option for additional shares. The company affirms that the funds will be sufficient to meet its working capital and operational needs through 2023. The offering was managed by Cantor Fitzgerald & Co., with H.C. Wainwright & Co. as co-manager. The offering is compliant with SEC regulations, and details are available on the SEC's website.
Celldex Therapeutics (Nasdaq: CLDX) has priced its underwritten public offering of 13,377,926 shares at $9.75 each, aiming to raise about $130.4 million. The offering includes a 30-day option for the underwriter to purchase an additional 2,006,688 shares. Proceeds will support ongoing clinical and preclinical development of product candidates and general corporate purposes. The offering is set to close on June 18, 2020, subject to customary conditions. The offering follows a prospectus supplement filed with the SEC on June 12, 2020.
Celldex Therapeutics (Nasdaq: CLDX) announced a proposed underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase an additional 15% of the shares. The company aims to utilize the proceeds for clinical and preclinical development of its product candidates and general corporate purposes. The final terms will depend on market conditions, and there is no guarantee regarding the completion or terms of the offering. Cantor Fitzgerald & Co. is the sole book-running manager for the offering.
Celldex Therapeutics (NASDAQ: CLDX) announced positive results from a Phase 1 study of its KIT inhibitor, CDX-0159, targeting mast cell-driven diseases. Presented at the EAACI Annual Congress 2020, the study showed CDX-0159 induced significant and long-lasting reductions in plasma tryptase levels, indicating effective mast cell suppression. The favorable safety profile and promising data support further development in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CINDU). Future studies are expected to start later this year, enhancing treatment options for patients.
Celldex Therapeutics (NASDAQ:CLDX) reported significant progress in its pipeline during Q1 2020, despite COVID-19 challenges. The company completed enrollment in the Phase 1 study of its KIT inhibitor, CDX-0159, set for presentation at the EAACI Annual Congress 2020. Celldex plans to expand CDX-0159's development for chronic urticaria and is preparing for a Phase 1 study of CDX-527 in advanced cancers. Q1 2020 financials showed revenues of $2.7 million, primarily from a $1.8 million milestone payment, while net loss decreased to $12.6 million. Celldex's cash is sufficient to fund operations into Q2 2021.
Celldex Therapeutics (NASDAQ: CLDX) announced that results from the Phase 1 study of CDX-0159 will be presented as a late-breaking poster at the EAACI Annual Congress 2020, taking place digitally from June 6-8, 2020. The study shows that CDX-0159, an anti-KIT monoclonal antibody, achieves dose-dependent reductions in serum tryptase levels, indicating a favorable safety profile. Following promising results, Celldex plans to expand CDX-0159's development into Phase 1b studies for chronic spontaneous and inducible urticaria.